184036-34-8

Basic information

• Product Name: N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide
• Synonyms: N-(4-chloro-3-methyl-2,3-dihydrooxazol-5-yl)-2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide;N-(4-chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide;N-(4-Chloro-3-methyl-oxazol-5-yl)-2-[2-(6-methylbenzo[1,3]dioxol-5-yl)acetyl]thiophene-3-sulfo;N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d]-[1,3]dioxol-5-yl)acetyl)thiophene-3;N-(4-chloro-3-methyl-oxazol-5-yl)-2-[2-(6-methylbenzo[1,3]dioxol-5-yl)acetyl]thiophene-3-sulfonamide;D07171;Sitax;N- (4- chloro- 3- Methyl- oxazol- 5- yl)- 2- [2- (6- Methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophen
• CAS NO: 184036-34-8
• Molecular Formula: C18H15ClN2O6S2
• Molecular Weight: 456.92
• Mol File: 184036-34-8.mol

Chemical Properties

• Melting Point: 42-45°
• Boiling Point: 663.9 °C at 760 mmHg
• Flash Point: 355.3 °C
• Appearance: /
• Density: 1.558
• Vapor Pressure: 2.25E-14mmHg at 25°C
• Refractive Index: 1.687
• Storage Temp.: 2-8°C
• PKA: 4.96±0.10(Predicted)
• CAS DataBase Reference: N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide(184036-34-8)
• EPA Substance Registry System: N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide(184036-34-8)

Safety Data

• Hazardous Substances Data: 184036-34-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-chloro-3-methyl-oxazol-5-yl)-2-[2-(6-methylbenzo[1,3]dioxol-5-yl)acetyl]-thiophene-3-sulfonamide is used as a pharmaceutical compound for the development of new drugs. Its unique chemical structure and functional groups make it a promising candidate for targeting specific biological pathways and receptors, potentially leading to the development of novel therapeutic agents.
Used in Chemical Research:
N(4chloro3methyloxazol5yl)2[2(6methylbenzo[1,3]dioxol5yl)acetyl]thiophene3sulfonamide is also used in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its diverse functional groups and chemical properties make it a valuable tool for exploring new reaction pathways and developing innovative synthetic methods.
Used in Material Science:
N-(4-chloro-3-methyl-oxazol-5-yl)-2-[2-(6-methylbenzo[1,3]dioxol-5-yl)acetyl]-thiophene-3-sulfonamide may have potential applications in the field of material science, particularly in the development of new materials with specific properties. Its unique chemical structure could be utilized to create materials with tailored characteristics, such as improved stability, enhanced reactivity, or novel optical or electronic properties.

Originator

Encysive (US)

InChI:InChI=1/C18H17ClN2O6S2/c1-10-5-13-14(27-9-26-13)7-11(10)6-12(22)16-15(3-4-28-16)29(23,24)20-18-17(19)21(2)8-25-18/h3-5,7,20H,6,8-9H2,1-2H3

Upstream product

• 210421-71-9 N-(4-chloro-3-methyl-5-isoxazolyl)-2-(N-methyl-N'-methoxy)aminocarbonyl-3-thiophenesulfonamide 
• 1006588-99-3 C₉H₅ClN₂O₄S₂ 
• 1008726-80-4 C₉H₉ClMgO₂ 
• 117661-72-0 (3,4-methylenedioxy)-6-methylbenzyl chloride 
• 184040-74-2 3{[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxylic acid 
• 20850-43-5 5-(chloromethyl)-1,3-benzodioxole 
• 7145-99-5 5-methyl-1,3-benzodioxole 

Relevant articles and documents

Methods and compositions for treatment of sleep apnea

Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.

METHODS AN COMPOSITIONS FOR TREATMENT OF AN INTERSTITIAL LUNG DISEASE

Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.

SUBSTITUTED THIOPHENES

Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Formulations of sitaxsentan sodium

Provided herein are stable lyophilized and oral formulations of sitaxsentan sodium. In certain embodiments the lyophilized formulations provided herein have improved stability upon reconstitution. Also provided are methods of making and using the formulations.

PROCESSES FOR THE PREPARATION OF 4-CHLORO-3-METHYL-5-(2-(2-(6-METHYLBENZO[D][1,3]DIOXOL-5-YL)ACETYL)-3-THIENYLSULFONAMIDO) ISOXAZOLE

Provided are processes for the preparation of 4-chloro-3-methyl-5-(2-(2-(6- methylbenzo[d][1,3Jdioxol-5-yl)acetyl)-3-thienylsulfonamido)isoxazole of formula (I), a compound useful for the treatment of endothelin-mediated disorders.

CRYSTALLINE N-(4-CHLORO-3-METHYL-5-ISOXAZOLYL)-2-[2-METHYL-4,5-(METHYLENEDIOXY)PHENYLACETYL]-THIOPHENE-3-SULFONAMIDE

Provided herein are polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide and pharmaceutical compositions thereof. Also provided are methods of treatment of endothelin-mediated disorders by administering a polymorph N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide or pharmaceutical compositions thereof.

POLYMORPHS OF N-(4-CHLORO-3-METHYL-5-ISOXAZOLYL)2-[2-METHYL-4,5-(METHYLENEDIOXY) PHENYLACETYL]THIOPHENE-3-SULFONAMIDE, SODIUM SALT

N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyl- acetyl]thiophene-3-sulfonamide,, sodium salt, is provided herein in the form of three polymorphs (Forms A, B and C). Forms A, B and C are specified by the peaks in their X-ray powder diffraction patterns, their absorption peaks in their infrared absorption spectra, their peaks in their Raman spectra and their melting points.

METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE

Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.

Sulfonamides for treatment of endothelin-mediated disorders

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides a

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.